Pharma & Biotech
-
Glaxo Moving Bulk of Its Research and Discovery Operations to Montgomery County
GlaxoSmithKline has decided to consolidate its global drug research and discovery operations into two big hubs with one of them in Upper Providence Township, writes Linda Loyd for Philly.com. The company, which already employs 5,000 people in the Philadelphia area, is planning to spend close to $250 million on the construction of four floors of…
-
Worldwide Branding Recognizes DrugDev’s Sherri Miller for Finance Management Excellence
Sherri Miller, DrugDev‘s Vice President of Finance and Accounting, has been recognized by Worldwide Branding for showing dedication, leadership and overall excellence in finance management. The world’s leading international personal branding organization which has its U.S. headquarters in Wayne honored Miller for her professional efforts and accomplishments. Miller is responsible for forecasting the company’s finances…
-
Local Life Science Innovators Make Greater Philadelphia One of the Best
Throughout an industry in which regions across the nation constantly jockey for prominence, Greater Philadelphia has remained a life science innovator that the world depends on. Greater Philadelphia boasts 90 colleges and universities, 100 hospitals, 1,600 life sciences companies, 11 million square feet, and the hearts and minds of up-and-coming millennials, according to the Philadelphia…
-
Six Montgomery County Schools to Receive Donations of Narcan Nasal Spray from Adapt
Governor Tom Wolf has announced that in accordance with its agreement with the state Department of Health, Radnor-based Adapt Pharma will supply free doses of Narcan, its emergency nasal-spray treatment for opioid overdoses, to 128 high schools across Pennsylvania including six in Montgomery County, writes Alison Burdo for Philadelphia Business Journal. Adapt announced in January…
-
GlaxoSmithKline’s Collegeville Facility Gambling on Antibiotics
GlaxoSmithKline’s Collegeville facility is leading the charge against superbugs with cutting edge antibacterial research, writes Stephanie Baker for Bloomberg. Most of Big Pharma is cutting back research in this realm, since it’s not as profitable as other specialized areas. GSK, meanwhile, has invested more than $1 billion over the last 10 years into researching antibiotics.…
-
Woman Breaks Big Pharma’s Glass Ceiling After Being Named CEO of GlaxoSmithKline
Emma Walmsley has been named the new CEO at GlaxoSmithKline, the United Kingdom’s largest drug manufacturer with facilities in Upper Merion and Upper Providence, breaking the glass ceiling in big pharmaceutical companies, writes Linda Loyd for the Philadelphia Inquirer. She will be the first woman to head Britain’s GSK, as well as the first woman…
-
Zika Vaccine of Plymouth Meeting’s Inovio Named Technology Breakthrough of the Year
Popular Mechanics, a magazine that serves as the country’s leading voice in technology, has named the progress made by Inovio Pharmaceuticals on its Zika virus vaccine the Technology Breakthrough of the Year. The Plymouth Meeting company has advanced its DNA-based Zika vaccine into trials in the U.S., Canada, and Puerto Rico. It expects results from…
-
Fort Washington’s Vitae Pharmaceuticals to Be Bought for $639 Million
Allergan, a global pharmaceutical company based in Dublin, Ireland, agreed Wednesday to buy Fort Washington-based Vitae Pharmaceuticals for $639 million, writes John George for the Philadelphia Business Journal. The deal has received the approval of both company’s boards of directors, as Allergan will pay Vitae stockholders $21 per share. Shares of the Montgomery County clinical…
-
Plymouth Meeting’s Inovio Pharmaceuticals Starts Testing Zika Vaccine in Puerto Rico
Plymouth Meeting’s Inovio Pharmaceuticals has started a clinical study of its experimental Zika vaccine on 160 healthy adult volunteers in Puerto Rico, after the territory declared a public health emergency over the virus’s outbreak, writes Linda Loyd for the Philadelphia Inquirer. The news gave an immediate boost to the company’s shares, which jumped by 4.63…
-
Merck Announces 148 Job Cuts in North Wales
Following its decision to stop promoting the heart drug Zontivity, Merck has announced that it is cutting 148 jobs at its North Wales campus, writes John George for the Philadelphia Business Journal. The cuts, which are effective Sept. 12th, come just a month after Merck announced it was moving more than 300 positions from Pennsylvania…
-
Valley Forge’s Indipharm Re-Launches as InClinica
Valley Forge’s clinical contract research organization Indipharm is being re-launched as InClinica by its new owner, Velocity Fund Partners, writes John George for the Philadelphia Business Journal. Jim Nolan, operating partner of Velocity Fund Partners, will serve as CEO of the newly re-branded InClinica. Dr. Edward J. Brennan Jr., founder and president of Indipharm, is…
-
Plymouth Meeting’s Inovio Pharmaceuticals Tests Zika Vaccine on First Volunteer
Plymouth Meeting’s Inovio Pharmaceuticals has injected the first volunteer with its experimental vaccine for the Zika virus, with results from the study expected later this year, writes Linda Loyd for the Philadelphia Inquirer. Both the Food and Drug Administration and Health Canada’s Health Products and Food Branch have given the green light to early-stage tests…
-
Fort Washington’s Madrigal Pharmaceuticals Completes Merger with Synta, Creates Leader in Field
Fort Washington’s Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, has announced the completion of its merger with Synta Pharmaceuticals. The combined company has more than $40 million in cash to advance its research and development efforts, including…
-
Merck Plans Layoffs at North Wales Facility
Merck has announced plans to lay off research-and-development workers at three East Coast sites, including its North Wales facility, writes Peter Loftus for The Wall Street Journal. The move is part of a shakeup of its early-stage drug development efforts and also includes a change in focus to the health effects of micro-organisms, which inhabit…
-
Conshohocken Doctor One of First in America to Implant New Drug for Opioid Addiction
Dr. Michael Frost of Conshohocken’s Frost Medical Group recently became one of the first doctors in America to implant Probuphine, a newly approved drug used to treat opioid addiction, in a patient, according to a staff report from 6ABC. Last month, the FDA approved Probuphine, an implant-type treatment for battling addiction. Among the first patients…
-
Plymouth Meeting’s Inovio Pharmaceuticals Gets Green Light to Start Human Testing of Zika Vaccine
Inovio Pharmaceuticals has received a green light from the Food and Drug Administration to start human testing of its experimental vaccine for the Zika virus, writes John George for the Philadelphia Business Journal. The Zika vaccine is being developed by the Plymouth Meeting-based biopharmaceutical company in partnership with South Korea’s GeneOne Life Science Inc. The companies…
-
Merck Buying California-Based Afferent Pharmaceuticals for a Cool $1.25 Billion
Merck has entered into a $1.25 billion deal to acquire California-based Afferent Pharmaceuticals, which is developing a treatment for chronic cough, writes John George for the Philadelphia Business Journal. Merck, which has a large research and manufacturing plant in Upper Gwynedd, anticipates the transaction will close in the third quarter of this year. Under the terms…
-
King of Prussia’s Trevena Begins Late-Stage Clinical Trials for New Pain Medicine
Trevena, a King of Prussia-based biopharmaceutical company, has started two late-stage clinical trials on its experimental pain medicine, oliceirdine, writes John George for the Philadelphia Business Journal. Trevena will test oliceirdine in patients suffering from moderate to severe pain following a bunionectomy to remove a bunion their toe, or from an abdominoplasty which removes excess…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
